.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Argus Health
Covington
Cantor Fitzgerald
Citi
Cipla
Accenture
Daiichi Sankyo
Healthtrust

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022224

« Back to Dashboard
NDA 022224 describes TRILIPIX, which is a drug marketed by Abbvie and is included in one NDA. It is available from four suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the TRILIPIX profile page.

The generic ingredient in TRILIPIX is choline fenofibrate. There are ninety-nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Summary for NDA: 022224

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 022224

Suppliers and Packaging for NDA: 022224

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRILIPIX
choline fenofibrate
CAPSULE, DELAYED RELEASE;ORAL 022224 NDA AbbVie Inc. 0074-3161 0074-3161-90 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3161-90)
TRILIPIX
choline fenofibrate
CAPSULE, DELAYED RELEASE;ORAL 022224 NDA AbbVie Inc. 0074-3162 0074-3162-90 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3162-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 45MG FENOFIBRIC ACID
Approval Date:Dec 15, 2008TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jan 7, 2025Product Flag?Substance Flag?YDelist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrengthEQ 135MG FENOFIBRIC ACID
Approval Date:Dec 15, 2008TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jan 7, 2025Product Flag?Substance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Healthtrust
McKesson
Federal Trade Commission
Chinese Patent Office
Daiichi Sankyo
Teva
Medtronic
Citi
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot